PURPOSE: Recently, concerns have arisen about metal-on-metal (MoM) total hip arthroplasty (THA). Therefore, the purpose of this cross-sectional cohort study was to describe the incidence of pain, pseudotumours, revisions and the relation between elevated metal ion levels, functional outcome and quality of life after MoM THA. METHODS: In 351 patients, 377 MoM THA with a fixed-size 38-mm head were evaluated with a mean follow-up of 30 months (range 11-58). Evaluation included pain, serum metal ions, patient-reported questionnaires (Short Form-36 [SF-36], Hip disability and Osteoarthritis Outcome Score [HOOS] and the Oxford Hip Score [OHS]) and radiological imaging. Sixteen patients did not participate in the screening. RESULTS: One hundred and eighteen (35 %) patients reported pain and showed significantly higher cobalt and chromium levels compared to patients without pain. Median serum cobalt levels were 4.4 μg/l (interquartile range [IQR] 6.6) and chromium levels were 3.6 μg/l (IQR 4.8). Patients with cobalt levels of ≤5 μg/l reported significantly better outcome on the SF-36 and HOOS. Fifty-seven pseudotumours were identified in 227 THAs. A revision rate of 19 % was observed. CONCLUSIONS: In conclusion, 35 % of the patients experienced pain after MoM THA. These patients showed significantly higher serum metal ion levels. The patient-reported questionnaires indicated significantly better outcome in patients with cobalt levels ≤5 μg/l.
PURPOSE: Recently, concerns have arisen about metal-on-metal (MoM) total hip arthroplasty (THA). Therefore, the purpose of this cross-sectional cohort study was to describe the incidence of pain, pseudotumours, revisions and the relation between elevated metal ion levels, functional outcome and quality of life after MoM THA. METHODS: In 351 patients, 377 MoM THA with a fixed-size 38-mm head were evaluated with a mean follow-up of 30 months (range 11-58). Evaluation included pain, serum metal ions, patient-reported questionnaires (Short Form-36 [SF-36], Hip disability and Osteoarthritis Outcome Score [HOOS] and the Oxford Hip Score [OHS]) and radiological imaging. Sixteen patients did not participate in the screening. RESULTS: One hundred and eighteen (35 %) patients reported pain and showed significantly higher cobalt and chromium levels compared to patients without pain. Median serum cobalt levels were 4.4 μg/l (interquartile range [IQR] 6.6) and chromium levels were 3.6 μg/l (IQR 4.8). Patients with cobalt levels of ≤5 μg/l reported significantly better outcome on the SF-36 and HOOS. Fifty-seven pseudotumours were identified in 227 THAs. A revision rate of 19 % was observed. CONCLUSIONS: In conclusion, 35 % of the patients experienced pain after MoM THA. These patients showed significantly higher serum metal ion levels. The patient-reported questionnaires indicated significantly better outcome in patients with cobalt levels ≤5 μg/l.
Authors: I B de Groot; M Reijman; C B Terwee; S Bierma-Zeinstra; M M Favejee; E Roos; J A Verhaar Journal: Osteoarthritis Cartilage Date: 2008-07-11 Impact factor: 6.576
Authors: David Fabi; Brett Levine; Wayne Paprosky; Craig Della Valle; Scott Sporer; Gregg Klein; Harlan Levine; Mark Hartzband Journal: Orthopedics Date: 2012-07-01 Impact factor: 1.390
Authors: Ryan K Takenaga; John J Callaghan; Nicholas A Bedard; Steve S Liu; Yubo Gao Journal: Clin Orthop Relat Res Date: 2013-04-09 Impact factor: 4.176
Authors: Harry S Hothi; Reshid Berber; Andreas C Panagiotopoulos; Robert K Whittaker; Camilla Rhead; John A Skinner; Alister J Hart Journal: Int Orthop Date: 2016-01-25 Impact factor: 3.075
Authors: Christiaan Smeekes; Arjen H G Cleven; Bart C H van der Wal; Stefan V Dubois; Remigio W Rouse; Bastiaan F Ongkiehong; Ron Wolterbeek; Rob G H H Nelissen Journal: Clin Orthop Relat Res Date: 2017-07-07 Impact factor: 4.176
Authors: C Smeekes; B J M Schouten; M Nix; B F Ongkiehong; R Wolterbeek; B C H van der Wal; R G H H Nelissen Journal: Skeletal Radiol Date: 2018-02-01 Impact factor: 2.199